SCHEMBL22875166

SCHEMBL22875166

CCC1CCN(C(=O)CCC(F)F)CC1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 1/20 0.44
GNAI3 P08754 5/20 0.43
GNAO1 P09471 5/20 0.43
GNAI1 P63096 5/20 0.43
DPP8 Q6V1X1 1/20 0.41
DPP7 Q9UHL4 1/20 0.41
CACNA1B Q00975 2/20 0.40
ITGB3 P05106 3/20 0.40
ITGA2B P08514 3/20 0.40
ALDH1A1 P00352 2/20 0.40
HSD11B1 P28845 1/20 0.40
EPHX2 P34913 1/20 0.38
KDM4E B2RXH2 1/20 0.38
MEN1 O00255 1/20 0.38
USP2 O75604 1/20 0.38
LMNA P02545 1/20 0.38
CYP3A4 P08684 1/20 0.38
HPGD P15428 1/20 0.38
KMT2A Q03164 1/20 0.38
HSD17B10 Q99714 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22874752 0.83 NPC1 (0.44) NPC1GNAI3GNAO1GNAI1DPP8
SCHEMBL18330354 0.82 GNAI3 (0.51) NPC1GNAI3GNAO1GNAI1ALDH1A1
SCHEMBL26297821 0.80 GNAI3 (0.51) NPC1GNAI3GNAO1GNAI1DPP8
SCHEMBL11981636 0.79 NPC1 (0.47) NPC1GNAI3GNAO1GNAI1ALDH1A1
SCHEMBL27429180 0.79 GNAI3 (0.60) NPC1GNAI3GNAO1GNAI1ITGB3
SCHEMBL21871765 0.79 HSD11B1 (0.47) NPC1GNAI3GNAO1GNAI1DPP8
SCHEMBL19681628 0.79 NPC1 (0.38) NPC1GNAI3GNAO1GNAI1DPP8
SCHEMBL22874747 0.78 NPC1 (0.53) NPC1GNAI3GNAO1GNAI1ITGB3
SCHEMBL4487574 0.77 EPHX2 (0.51) NPC1GNAI3GNAO1GNAI1ALDH1A1
SCHEMBL19021775 0.77 GNAI3 (0.50) GNAI3GNAO1GNAI1ITGB3ITGA2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11753397-B2 Cereblon binders for the degradation of ikaros C4 THERAPEUTICS, INC. (US) 2023-09-12 US disclosed
US-20210009559-A1 CEREBLON BINDERS FOR THE DEGRADATION OF IKAROS C4 THERAPEUTICS, INC. (US) 2021-01-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11753397-B2 Cereblon binders for the degradation of ikaros CRBN, IKZF1, IKZF3 NPC1 2155/4885GNAI3 1551/4885GNAO1 1521/4885
US-20210009559-A1 CEREBLON BINDERS FOR THE DEGRADATION OF IKAROS CRBN, IKZF1, IKZF3 NPC1 2645/4885GNAI3 2181/4885GNAO1 1777/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.